Peer-reviewed veterinary case report
Treatment results for T cell lymphoma in 35 dogs with chemotherapy
By E. Morgan et al.·Published in Veterinary and Comparative Oncology·2018·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
- Species:
- dog
Plain-English summary
A group of 35 dogs diagnosed with T cell lymphoma (a type of cancer) received a combination of chemotherapy drugs including lomustine, vincristine, procarbazine, and prednisolone. The treatment led to a median survival time of about 507 days, with many dogs showing significant improvement. In fact, 29 of the dogs had a complete response to the treatment, meaning their cancer went into remission. While some dogs experienced mild side effects, the overall results suggest that this chemotherapy protocol could be an effective first-line treatment for T cell lymphoma in dogs.
People also search for: dog T cell lymphoma treatment · canine lymphoma chemotherapy · dog cancer survival rates
Abstract
Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investigating alternative protocols for T cell lymphoma. This study investigated the use of a modified lomustine, vincristine, procarbazine and prednisolone protocol as a first line treatment in 35 dogs with T Cell lymphoma. Median progression free survival (PFS) time for all 35 dogs was 431 days with a 6-month, 1-year, 2-year, and 3-year PFS of 69%, 54%, 29%, and 12%. Median survival time (MST) was 507 days. Twenty-nine dogs attained a complete response and had a median PFS time of 509 days. Thirty dogs experienced adverse events during the protocol, with 73% of these being grade 1 or 2. This protocol has shown increased median PFS time and MST compared with previous studies and suggests its use as a first line chemotherapy protocol against canine T cell lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/30117253